2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2016
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, Association E. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-531. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOral direct acting antiviralsClinical improvementChild-PughLiver transplantationActing antiviralsAdvanced liver diseaseChronic hepatitis CLiver transplant candidatesLow MELD scoresRemarkable clinical improvementHepatitis C virusDAA therapyDelta MELDDelta-albuminDAA combinationsHepatitis CMELD scoreViral eradicationCumulative incidenceLiver dysfunctionTransplant candidatesAntiviral therapyLiver diseaseLiver function